Patents by Inventor Lian WU

Lian WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10414774
    Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jared N. Cumming, Kevin D. Dykstra, Alan Hruza, Derun Li, Hong Liu, Haiqun Tang, Brandon M. Taoka, Andreas Verras, Shawn P. Walsh, Wen-Lian Wu
  • Patent number: 10414775
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John P. Caldwell, Mary Ann Caplen, Jared N. Cumming, Kevin D. Dykstra, Alan Hruza, Claire Lankin, Derun Li, Hong Liu, Amy McCracken, Brian McKittrick, Ashwin Rao, Jayaram Tagat, Haiqun Tang, Brandon M. Taoka, Andreas Verras, Shawn P. Walsh, Wen-Lian Wu, Tianyuan Zhang
  • Publication number: 20190218224
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
    Type: Application
    Filed: August 10, 2017
    Publication date: July 18, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John P. Caldwell, Mary Ann Caplen, Jared N. Cumming, Kevin D. Dykstra, Alan Hruza, Claire Lankin, Derun Li, Hong Liu, Amy McCracken, Brian McKittrick, Ashwin Rao, Jayaram Tagat, Haiqun Tang, Brandon M. Taoka, Andreas Verras, Shawn P. Walsh, Wen-Lian Wu, Tianyuan Zhang
  • Publication number: 20190218223
    Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
    Type: Application
    Filed: August 10, 2017
    Publication date: July 18, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jared N. Cumming, Kevin D. Dykstra, Alan Hruza, Derun Li, Hong Liu, Haiqun Tang, Brandon M. Taoka, Andreas Verras, Shawn P. Walsh, Wen-Lian Wu
  • Publication number: 20190016734
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I) or a tautomer thereof and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, R3, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: February 6, 2017
    Publication date: January 17, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Jared N. Cumming, Brandon M. Taoka, Xing Dai
  • Patent number: 10071998
    Abstract: In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, ring A, RA, m, ring B, RB, and n are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: September 11, 2018
    Inventors: Wen-Lian Wu, Shuwen He, Shawn P. Walsh, Jared N. Cumming
  • Publication number: 20170369484
    Abstract: In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, ring A, RA, m, ring B, RB, and n are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Shuwen He, Shawn P. Walsh, Jared N. Cumming
  • Patent number: 9732088
    Abstract: In its many embodiments, the present invention provides certain C2-carbocyclic iminothiazine dioxide compounds, including compounds Formula (I); or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, ring A, RA, m, ring B, RB, n, ring C, RC and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: August 15, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shawn P. Walsh, Jared N. Cumming, Shuwen He, Brandon M. Taoka, Quang T. Truong, Wen-Lian Wu
  • Patent number: 9725468
    Abstract: In its many embodiments, the present invention provides certain C5-spiro iminothiadiazine dioxide compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoisomers, wherein RL, X, Y, R1A, R1B, R2, R3, m, and RA are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: August 8, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jack D. Scott, Wen-Lian Wu, Jared N. Cumming
  • Patent number: 9692294
    Abstract: A control circuit in a power factor correction (PFC) circuit includes: a multiplier, used for multiplying a voltage sampling signal by a feedback signal, and outputting a first signal; and a waveform generating module, used for generating a second signal related to a filter capacitor connected in parallel to an input end and/or an output end of a rectifier bridge. A control signal for controlling a state of a main switch transistor is generated by using the first signal, the second signal, and a current sampling signal of the main switch transistor in the PFC circuit.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: June 27, 2017
    Assignee: INVENTRONICS (HANGZHOU), INC.
    Inventors: Delai Jiang, Liang'an Ge, Lian Wu
  • Publication number: 20170114065
    Abstract: In its many embodiments, the present invention provides certain C2-carbocyclic iminothiazine dioxide compounds, including compounds Formula (I); or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, ring A, RA, m, ring B, RB, n, ring C, RC and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: May 28, 2015
    Publication date: April 27, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Shawn P. Walsh, Jared N. Cumming, Shuwen He, Brandon M. Taoka, Quang T. Truong, Wen-Lian Wu
  • Patent number: 9511341
    Abstract: A method for preparing acetazolamide sodium powder for injection is provided. The method includes steps of providing an acetazolamide sodium solution; and aseptically spray drying the acetazolamide sodium solution to obtain the acetazolamide sodium powder.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: December 6, 2016
    Assignee: Sunny Pharmtech Inc.
    Inventors: Yen-Chih Lin, Yon-Lian Wu
  • Patent number: 9499502
    Abstract: The present invention discloses certain iminothiazine compounds and mono- and dioxides thereof, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoisomers, wherein each of variables shown in the formula are as defined herein. The compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and uses, including Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: November 22, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Duane A. Burnett, Andrew W. Stamford, Jared N. Cumming, Chad E. Bennett, Eric J. Gilbert, Jack D. Scott, Younong Yu, Xuanjia Peng
  • Patent number: 9453034
    Abstract: In its many embodiments, the present invention provides certain C2-azaspirosubstituted iminothiazine dioxide compounds. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: September 27, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric J. Gilbert, Jared N. Cumming, Jack D. Scott, Wen-Lian Wu, Duane A. Burnett, Andrew W. Stamford
  • Publication number: 20160222032
    Abstract: In its many embodiments, the present invention provides certain C5-spiro iminothiadiazine dioxide compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoisomers, wherein RL, X, Y, R1A, R1B, R2, R3, m, and RA are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: September 8, 2014
    Publication date: August 4, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jack D. Scott, Wen-Lian Wu, Jared N. Cumming
  • Patent number: D858806
    Type: Grant
    Filed: June 10, 2018
    Date of Patent: September 3, 2019
    Assignees: Haining Xincheng Electronics Co., LTD.
    Inventors: Jianxin Pan, Lian Wu, Hongbo Li
  • Patent number: D872038
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 7, 2020
    Inventors: Jianxin Pan, Lian Wu, Hongbo Li
  • Patent number: D872320
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: January 7, 2020
    Inventors: Jianxin Pan, Lian Wu, Hongbo Li
  • Patent number: D872321
    Type: Grant
    Filed: October 6, 2018
    Date of Patent: January 7, 2020
    Inventors: Jianxin Pan, Lian Wu, Hongbo Li
  • Patent number: D873783
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: January 28, 2020
    Inventors: Jianxin Pan, Lian Wu, Hongbo Li